MALVERN, Pa. , May 21, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that the Company presented a poster at the 2018 International Investigative Dermatology
MALVERN, Pa. , May 2, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM) (the Company), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces it has confidentially submitted a registration statement to the United States
MALVERN, Pa. , April 26, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that the Company expects to release its results for the year ended December 31, 2017 on
